The present disclosure relates to the technical field of pharmaceutical formulations and particularly provides, in the specification, a stable imidazo[1,2-a]pyridine derivative pharmaceutical composition, a preparation method therefor, and use thereof. The pharmaceutical composition comprises an active pharmaceutical ingredient and auxiliary materials, wherein the active pharmaceutical ingredient is (azetidin-1-yl)(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)methanone citrate; the auxiliary materials include one or more selected from cyclodextrin, a salt of cyclodextrin, propylene glycol, and PEG400.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
2.
SIRNA FOR INHIBITING XDH GENE EXPRESSION AND MODIFIER AND USE THEREOF
Provided siRNA for inhibiting XDH gene expression and a modifier and use thereof. The siRNA comprises a sense strand and an antisense strand. The sense strand and/or the antisense strand have a length in the range of 19-25 nucleotides, and the antisense strand is reversely complementary to a segment on a target gene; and the sense strand has a nucleotide sequence as shown in SEQ ID NO: 1-14, and the antisense strand has a nucleotide sequence as shown in SEQ ID NO: 18-31. siRNA molecules and modified siRNA molecules have high stability and/or high inhibitory activity. Ligand-conjugated siRNA molecules have good liver targeting performance and the capability to promote cell endocytosis while maintaining high inhibitory activity and stability, can reduce the impact on other tissues or organs and reduce the amount of siRNA molecules used, and can achieve the purposes of reducing toxicity and reducing costs.
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (Chine)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
LIVZON PHARMACEUTICAL GROUP INC. (Chine)
Inventeur(s)
Ding, Ke
Liu, Lianchao
Wang, Zhen
Chinnaiyan, Arul M.
Paroli, Abhijit
Abrégé
The present invention provides an NSD protein degradation agent and a use thereof. Specifically, the present invention provides a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3/PSA, AR, NKX3.1, and GSPT1 via target ubiquitination, and therefore can be used to treat indications related to abnormal expression of proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3/PSA, AR, NKX3.1, and GSPT1.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
4.
Dry Suspension Granules for Dry Suspension and Preparation Method Thereof
Dry suspension granules for dry suspension, including the dry suspension made of the said dry suspension granules, and preparation method thereof are provided. Such-The dry suspension granules contain anionic gel and cationic polymer. The weight ratio of the anionic gel and the cationic polymer is (0.5-50):1.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C08J 3/00 - Procédés pour le traitement de substances macromoléculaires ou la formation de mélanges
C08L 5/00 - Compositions contenant des polysaccharides ou leurs dérivés non prévus dans les groupes ou
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C08L 29/04 - Alcool polyvinyliqueHomopolymères ou copolymères d'esters partiellement hydrolysés d'alcools non saturés avec des acides carboxyliques saturés
5.
PIKFYVE PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (Chine)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
LIVZON PHARMACEUTICAL GROUP INC. (Chine)
Inventeur(s)
Ding, Ke
Chinnaiyan, Arul M.
Li, Chungen
Wang, Zhen
Qiao, Yuanyuan
Abrégé
A PIKfyve protein degradation agent and the use thereof. Specifically, provided is a compound having the structure as represented by formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can target and degrade the PIKfyve protein by means of the ubiquitin-proteasome pathway, and therefore the compound can be used for treating indications mediated by the abnormal expression of the PIKfyve protein.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
C07D 239/47 - Un atome d'azote et un atome d'oxygène ou de soufre, p. ex. cytosine
A crystal form A of a compound shown in formula I is prepared for the first time in the present invention. The form has important significance for improving the characteristics such as drug production, quality control, and solid oral preparation development prospects. The physical and chemical stability evaluation result shows that the crystal form A is a hydrate and does not lose water and does not have hygroscopicity under conventional conditions; moreover, the stability is obviously superior to that of an amorphous form and a crystal form E under high temperature, high humidity, acceleration experiments and illumination experiments. Furthermore, the fluidity of the crystal form A is superior to that of the crystal form E and the amorphous form. Finally, the bioavailability of the crystal form A is obviously higher than that of the amorphous form. On the basis of good physical and chemical stability, fluidity and bioavailability of the crystal form A, the crystal form A has great potential in subsequent development and production.
A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (Chine)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
LIVZON PHARMACEUTICAL GROUP INC. (Chine)
Inventeur(s)
Ding, Ke
Chinnaiyan, Arul M.
Yang, Jianzhang
Chang, Yu
Zhou, Licheng
Zhou, Kaijie
Wang, George Xiaoju
Wang, Zhen
Huang, Weixue
Zhou, Fengtao
Abrégé
The present invention relates to an aryl substituent-containing degradation agent for cyclin-dependent kinase 12/13 (CDK12/13), a preparation method therefor, and a pharmaceutical composition and use thereof. The degradation agent for CDK12/13 of the present invention has a structure represented by formula (I). The compound can be used as a protein kinase degradation agent, and can effectively and highly selectively degrade a CDK12/13 protein and inhibit proliferation, migration, and invasion of various tumor cells.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (Chine)
LIVZON PHARMACEUTICAL GROUP INC. (Chine)
Inventeur(s)
Ding, Ke
Lei, Chong
Liu, Rong
Wang, Yongxing
Huang, Weixue
Lu, Xuzhi
Abrégé
Provided in the present invention are a compound having a skeleton structure as represented by formula (I) or a pharmaceutically acceptable salt, an isotope derivative and a solvate thereof, or a stereoisomer, a geometric isomer and a tautomer thereof, or a prodrug molecule, a metabolite and a pharmaceutical composition thereof, and the use thereof. The compound involved in the present invention can efficiently inhibit the kinase activity of HPK1, has a relatively strong signal inhibition effect on a downstream pathway thereof, can be used for preparing an anti-tumor drug, and can also be used for preparing a drug for preventing and treating inflammatory diseases.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/4995 - Pyrazines ou pipérazines formant une partie de systèmes cycliques pontés
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
An enteric-coated pellet, a method for preparing the same and a formulation comprising the same are provided. The enteric-coated pellet can be an ilaprazole enteric-coated pellet.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
10.
USE OF ILAPRAZOLE IN REGULATING INTESTINAL MICROECOLOGY
The present invention relates to use of ilaprazole or a pharmaceutically acceptable salt thereof in regulating intestinal microecology, particularly in regulating the abundance of Bacteroidota bacteria and Bacillota bacteria, and also relates to use of ilaprazole in reducing the risk of pulmonary infection and regulating gastric microecology and serum gastrin. Ilaprazole is especially beneficial to the treatment of Helicobacter pylori, and is more suitable for an individual in need of long-term medication, such as a patient with a gastroesophageal reflux disease.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
11.
DRY SUSPENSION PARTICLES FOR DRY SUSPENSION, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to dry suspension particles used for dry suspension, dry suspension containing the dry suspension particles, a preparation method therefor and a use thereof. The dry suspension particles comprise an anionic gel and a cationic polymer, wherein the weight ratio of the anionic gel to the cationic polymer is (0.5~50):1.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; vaccines; biological
preparations for veterinary purposes; veterinary vaccines;
immunostimulants; biological preparations for medical
purposes; crude medicines; dietetic substances adapted for
medical use; mouthwashes for medical purposes; medicinal
tea.
13.
ENTERIC PELLET, PREPARATION METHOD THEREFOR, AND PREPARATION COMPRISING SAME
The present invention relates to an enteric pellet, a preparation method therefor, and a preparation comprising same, and particularly relates to an ilaprazole enteric pellet, a preparation method therefor, and a preparation comprising same.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; injectable pharmaceuticals;
pharmaceutical preparations for the treatment of
genitourinary diseases, namely, urological diseases,
infertility, sexually transmitted diseases, inflammatory
pelvic diseases; medicines for veterinary purposes; drug
delivery agents in the form of powders that provide
controlled release of the active ingredients for a wide
variety of pharmaceuticals; depuratives; sanitizing wipes;
pharmaceutical preparations for the treatment of hormonal
disorders; fertility enhancement preparations; estrogen
pharmaceutical preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Diagnostic preparations for medical purposes; chemical
reagents for medical or veterinary purposes; reagent paper
for medical purposes; diagnostic biomarker reagents for
medical purposes; chemical preparations for the diagnosis of
pregnancy; antibacterial handwashes; immunostimulants;
diagnostic preparations for veterinary purposes; reagent
paper for veterinary purposes; tissues impregnated with
pharmaceutical lotions. Testing apparatus for medical purposes; medical apparatus
and instruments; apparatus for use in medical analysis;
diagnostic apparatus for medical purposes; analysers for
bacterial identification for medical purposes; apparatus for
DNA and RNA testing for medical purposes; sanitary masks for
medical purposes; blood testing apparatus.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Hormonal preparations; hormones for medical purposes; veterinary pharmaceutical preparations for the treatment of hormonal disorder of livestock; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; depuratives for the body; sanitizing wipes; pharmaceutical preparations for the treatment of hormonal disorders; fertility enhancement preparations; estrogen preparations; hormones for medical use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; drugs for medical purposes;
medical preparations for slimming purposes; food for babies;
raw material drugs; prepared Chinese medicines; antibiotics;
biochemical drugs; medical preparations for the blood;
dietetic substances adapted for medical use.
The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 μm, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere.
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Medicines for the treatment of gastrointestinal diseases, for human purposes; [ Pharmaceutical products for the prevention and treatment of cancer, for human purposes; Tumor suppressing agents, for human purpose; ] Antibacterial pharmaceuticals; [ Cardiovascular pharmaceuticals; ] Pharmaceuticals, namely, anti-infectives; [ Medical preparations for slimming purposes; Food for babies; Bulk drugs, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Bulk drug in the nature of a pharmaceutical preparation for the treatment of cardiovascular disease, hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cardiovascular disease, hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cancer; Antibiotics; Biochemical medicines for the treatment of pneumonia, urinary tract infection, gynecological infections, skin and skin structure infections, meningitis, septicemia, cancer, diabetes, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; ] Biochemical drugs for treatment of gastrointestinal diseases [ ; Blood products, namely, immunoglobulins for medical or clinical use; Blood products for medical purposes, namely, blood plasma, reagent blood cells; Blood products for medical purposes, namely, blood plasma products, red blood cell products, and leukocyte products; Dietetic foods adapted for medical use; Dietetic beverages adapted for medical purposes ] [ Medical apparatus for detecting cancer; Medical device for treating cancer; Medical apparatus and instruments for use in surgery; Medical device and surgical instrument for use in diagnosis and surgery of the gastro-intestinal tract; Ultrasound diagnostic apparatus; X-ray diagnostic apparatus; Dental instruments, namely, oral irrigators; Drills for dental applications; Orthodontic machines and instruments, for dental purposes; Weight lifting machines for physical therapy; Foam rollers for use in physical therapy; Manually-operated exercise equipment for physical therapy purposes; Hearing aids; Baby bottles; Contraceptive apparatus, non-chemical; Artificial limbs; Orthopaedic belts; Orthopaedic knee bandages; Orthopaedic hip prostheses; Sanitary masks for medical purposes; Gloves for medical purposes ]
23.
USE OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF ANTI-ENTEROVIRUS 71 DRUG
NATIONAL ENGINEERING RESEARCH CENTER FOR MODERIZATION OF TRADITIONAL CHINESE MEDICINE (Chine)
Inventeur(s)
Tao, Desheng
Zeng, Yongqing
Cao, Hui
Guan, Yi
Abrégé
A traditional Chinese medicine composition for preventing and treating swine influenza, preparation method and use thereof, said traditional Chinese medicine composition is prepared by using Herba Houttuyniae 21.4wt%, Caulis Lonicerae 17.9wt%, Radix Isatidis 14.3wt%, Rhizoma Osmundae 10.7wt%, Radix Sophorae Tonkinensis 7.1wt%, Radix Heraclei Scabridi 7.1wt%, Rhizoma Paridis 7.1wt%, Herba Artemisiae 7.1wt%, Rhizoma Belamcandae 7.1wt%.
Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
26.
Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof
A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its active ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %, radix angelicae dahuricae 7.1 wt. %, rhizoma paridis 7.1 wt. %, herba artemisiae annuae 7.2 wt. %, and rhizoma iridis tectoris 7.2 wt. %. This Chinese traditional medicine composition could be made into any regular medicinal types, for example, oral solutions, tablets, capsules, pellets and injection solution, etc. Modified preparation methods for this Chinese traditional medicine composition, as well as the use of the same in preparation of medicines and health foods for prevention or treatment of avian influenza were also provided in present invention. This Chinese traditional medicine composition could effectively prevent and treat avian influenza. It was a safer, more easily-obtained, and inexpensive anti-avian influenza drug.
A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its active ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %, radix angelicae dahuricae 7.1 wt. %, rhizoma paridis 7.1 wt. %, herba artemisiae annuae 7.2 wt. %, and rhizoma iridis tectoris 7.2 wt. %. This Chinese traditional medicine composition could be made into any regular medicinal types, for example, oral solutions, tablets, capsules, pellets and injection solution, etc. Modified preparation methods for this Chinese traditional medicine composition, as well as the use of the same in preparation of medicines and health foods for prevention or treatment of avian influenza were also provided in present invention. This Chinese traditional medicine composition could effectively prevent and treat avian influenza. It was a safer, more easily-obtained, and inexpensive anti-avian influenza drug.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
Traditional Chinese medical compositions with effects of preventing and treating avian influenza (AI), active ingredients of which consist of Herba houttuyniae 21.4 wt.%, Caulis lonicerae 17.9 wt.%, Radix isatidis 14.3 wt.%, Rhizoma dryopteridis 10.7 wt.%, Radix sophorae 7.1 wt.%, Radix angelicae 7.1 wt.%, Rhizoma paridis 7.1 wt.%, Herba artemisiae 7.2 wt.%, Rhizoma belamcandae 7.2 wt.%. The present compositions can be made into any one of conventional dosage forms, such as oral solutions, tablets, capsules, granules and injections etc. Improved processes for preparation and usage in the manufacture of medicaments and functional foods for preventing and treating AI of the present compositions are also provided.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; drugs for medical purposes;
medical preparations for slimming purposes; food for babies;
raw material drugs; prepared Chinese medicines; antibiotics;
biochemical drugs; medical preparations for the blood;
dietetic substances adapted for medical use.
30.
LIVZON LIVESON Z L UVZON BEAUTIFUL PRETTY GLORIOUS JEWELRY BEAD DROP
